Clinical Investigation

You have free access to this content

Carbon-coated Stents in Patients with Acute Coronary Syndromes

  1. Jochen Wöhrle MD FESC*,
  2. Thorsten Nusser MD,
  3. Simone Langenwalder,
  4. Vinzenz Heombach MD,
  5. Matthias Kochs MD

Article first published online: 25 AUG 2008

DOI: 10.1002/clc.20295

Issue

Clinical Cardiology

Clinical Cardiology

Volume 32, Issue 6, pages E1–E6, June 2009

Additional Information

How to Cite

Wöhrle, J., Nusser, T., Langenwalder, S., Heombach, V. and Kochs, M. (2009), Carbon-coated Stents in Patients with Acute Coronary Syndromes. Clin Cardiol, 32: E1–E6. doi: 10.1002/clc.20295

Author Information

  1. Department of Internal Medicine II, University of Ulm, Ulm, Germany

*Director Catheterization Labs Department of Internal Medicine II University of Ulm Robert-Koch-Strasse-8 89081 Ulm, Germany

Publication History

  1. Issue published online: 30 JUN 2009
  2. Article first published online: 25 AUG 2008
  3. Manuscript Accepted: 17 SEP 2007
  4. Manuscript Received: 23 JUN 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (107K)

References

  • 1
    Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, et al.: Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105–1113.
  • 2
    Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, et al.: Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093–1104.
  • 3
    Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, et al.: Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009–1019.
  • 4
    Nordmann AJ, Briel M, Bucher HC: Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784–2814.
  • 5
    Park DW, Park SW, Park KH, Lee BK, Kim YH, et al.: Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352–356.
  • 6
    Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126–2130.
  • 7
    Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, et al.: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803–2809.
  • 8
    Chen MS, John JM, Chew DP, Lee DS, Ellis SG, et al.: Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260–1264.
  • 9
    Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, et al.: Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004; 147: 317–322.
  • 10
    Morice MC, Bestehorn HP, Carrié D, Macaya C, Verheye S, et al.: Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. Euro Interv 2006; 2: 45–52.
  • 11
    Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–231.
  • 12
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–1323.
  • 13
    Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, et al.: Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798–806.
  • 14
    Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, et al.: A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879–1885.
  • 15
    Weber F, Schneider H, Schwarz C, Holzhausen C, Petzsch M, et al.: Sirolimus-eluting stents for percutaneous coronary intervention in acute myocardial infarction Lesson from a case-controlled comparison of bare metal versus drug-eluting stents in thrombus-laden lesions. Z Kardiol 2004; 93: 938–943.
  • 16
    Stone GW, Brodie BR, Griffin JJ, Costantini C, Morice MC, et al.: Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation 1999; 99: 1548–1554.
  • 17
    Sick PB, Gelbrich G, Kalnins U, Erglis A, Bonan R, et al.: Comparison of early and late results of a Carbofilm-coated stent versus a pure high-grade stainless steel stent (the Carbostent-Trial). Am J Cardiol 2004; 93: 1351–1356.
  • 18
    Danzi GB, Capuano C, Sesana M, Baglini R, Bartorelli AL, et al.: Six-mo clinical and angiographic outcomes of the Tecnic Carbostent coronary system: the phantom IV study. J Invasive Cardiol 2004; 16: 641–644.
  • 19
    Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, et al.: Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41: 1283–1288.
  • 20
    Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, et al.: Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 10: 2816–2821.
  • 21
    Van de Werf F: Drug-eluting stents in acute myocardial infarction. N Engl J Med 2006; 355: 1169–1170.
Get PDF (107K)